Antipsychotics in the treatment of first-episode schizophrenia

Pharmaceutical Journal

Volumn 270, Issue 7241, 2003, Pages 405-408

  Feetam, Celia ^a   Donoghue, John ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; COGNITIVE DEFECT; COST OF ILLNESS; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MENTAL HEALTH SERVICE; PATHOPHYSIOLOGY; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0037460938     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic agents for the treatment of schizophrenia. London: NICE; 2002.
2. Cannon M, Jones P. Schizophrenia. J Neurol Neurosurg Psychiatr 1996;61:604-13.
3. Jablensky A. Schizophrenia: epidemiology. Curr Opin Psychiatr 1999;12:19-28.
4. Hojaij RC. Reappraisal of dementia praecox: focus on clinical psychopathology. World J Biol Psychiatr 2000;1:43-54.
5. Where next with psychiatric illness? (editorial). Nature 1988;336:95-6.
6. World Health Organization. The ICD-10 classification of mental and behavioural disorders. Geneva: WHO; 1992.
7. Pull CB. Diagnosis of schizophrenia: a review. In World Psychiatric Association series "Evidence and experience in psychiatry, volume 2: Schizophrenia." Maj M, Sartorius N (editors). Chichester: John Wiley & Sons Ltd; 1999. pp1-37.
8. Shultz SK, Andreasen NC. Schizophrenia. Lancet 1999;353: 1425-30.
9. Häfner H, Maurer K, Löffler W, an der Heiden W, Munk-Jørgensen P, Hambrecht M, et al. The ABC Schizophrenia study: a preliminary overview of the results. Soc Psychiatr Psychiatr Epidemiol 1998;33:380-6.
10. Hafner H, an der Heiden W. Epidemiology of schizophrenia. Can J Psychiatr 1997;42:139-51.
11. Jablensky A, Sartorius N, Emberg G, Anker M, Korten A, Cooper JE, et al. Schizophrenia: manifestations, incidence, and course in different cultures: a World Health Organization ten-country study. Psychol Med 1992;20:1-27.
12. Riley EM, McGovern D, Mockler D, Doku VCK, Ceallaigh S, Fannon DG, et al. Neuropsychological functioning in first-episode psychosis: evidence of specific deficits. Schiz Res 2000;43:47-55.
13. Frangou S, Byrne P. How to manage first-episode schizophrenia (editorial). BMJ 2000;321:522-3.
14. DeQuardo J. Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. J Clin Psych 1998;59(Suppl 19):9-17.
15. McGorry PD, Krstev H, Harrigan S. Early detection and treatment delay: implications for outcome in early psychosis. Curr Opin Psychiatr 2000;13:37-43.
16. Robinson DG, Woerner MG, Alvir JMJ, Geisler S, Koreen A, Sheitman B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psych 1999;156:544-9.
17. Lincoln C, Harrigan S, McGorry P. Understanding the topography of the early psychosis pathways. Br J Psychiatr 1998;172(Suppl 33):21-5.
18. McGorry P, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 1996;22:305-26.
19. Wyatt RJ, Damiani LM, Henter ID. First-episode schizophrenia. Br J Psych 1998;172(Suppl 33):77-83.
20. Lieberman JA, Alvir JM, Woerner M, Degreef G, Bilder RM, Ashtari M, et al. Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital. Schizophr Bull 1992;18:351-71.
21. Szymanski SR, Cannon TD, Gallacher F, Erwin RJ, Gur RE. Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatr 1996;153:519-25.
22. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatr 1992;149:1183-8.
23. Remington G, Kapur S, Zipursky RB. Pharmacotherapy of first-episode schizophrenia. Br J Psychiatr 1998;172(Suppl 33):66-70.
24. Power P, Elkins K, Adlard S, Curry C, McGorry P, Harrigan S. Analysis of the initial treatment phase in first-episode psychosis. Br J Psychiatr 1998;172(Suppl 33):71-6.
25. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
26. Wing JK, Beevor AS, Curtis RH, Park SGB, Hadden S, Burns A. Health of the Nation Outcome Scales (HoNOS) Research and development. Br J Psychiatr 1998;172:11-18.
27. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Publication no 76-338. Rockville, MD: National Institute of Mental Health;1976.
28. Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatr 1999;60(Suppl 23):5-9.
29. Wieck A, Haddad P. Hyperprolactinaemia caused by antipsychotic drugs. This common side effect needs more attention (editorial). BMJ 2002;324:250-2.
30. Robinson D, Woerner MG, Alvir J, Bilder R, Goldman R, Feisler S et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatr 1999;56:241-7.
31. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003;28:9-26.
32. Donoghue J. Use of the number needed to treat to evaluate clinical trials of quetiapine and other atypical antipsychotics. Eur Neuropsychopharmacol 2000;10(Suppl 3):S301-S302.
33. Thomas CS, Lewis S. Which atypical antipsychotic? Br J Psychiatr 1998;172:106-9.
34. Emsley RA and the Risperidone Working Group. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicentre study. Schizophr Bull 1999;25:721-9.
35. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasly C Jr, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatr 1999;156:79-87.
36. Coulovrat C, Dondey-Nouvel L. Safety of amisulpride. A review of eleven clinical studies. Int Clin Psychopharmacol 1999;14:209-18.
37. Puech A, Fleurot O, Rein W and the Amisulpride Study Group. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study versus haloperidol. Acta Psychiatr Scand 1998;98:65-72.
38. Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Leisler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatr 1997;58:205-11.
39. Beasley CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-37.
40. Barnes TRE, McPhillips MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatr 1999;174(Suppl 38):34-43.
41. Marder S, Meibach R. Risperidone in the treatment of schizophrenia. Am J Psychiatr 1994;151:825-35.
42. Peuskens J and the Risperidone Study Group. Risperidone in the treatment of chronic schizophrenic patients: an international multicentre double-blind comparative study versus haloperidol. Br J Psychiatr 1995;166:712-26.
43. Borison RL, Arvanitis LA, Miller BG and the US Quetiapine Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996; 16:158-69.
44. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG, Seroquel Study Group. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatr 1997;54:549-57.
45. Arvanitis LA, Miller BG and the "Seroquel" international study group, trial 13. Multiple fixed doses of quetiapine in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatr 1997;42:233-46.
46. Copolov DL, Link CGG, Kowalcyk B. A multicentre double-blind randomised comparison of quetiapine (ICI 204, 636, Seroquel) and haloperidol in schizophrenia. Psychol Med 2000;30:95-106.
47. Simons WR, Bassi R, White, R. Antipsychotic compliance evalution: a population-based managed care study of persistence with initially prescribed antipsychotic medication. Poster presented at the ISPOR 4th Annual European Congress, 11-13 November 2001, Cannes.